FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306252007> ?p ?o ?g. }

• W4306252007 endingPage "S246" @default.
• W4306252007 startingPage "S245" @default.
• W4306252007 abstract "INTRODUCTION: Treatment of advanced melanoma has evolved dramatically recently. Randomized trials now support omitting completion lymph node dissection (CLND) and offering adjuvant systemic therapy for many patients with sentinel lymph node–positive melanoma. Recent data from an international melanoma consortium suggest wide variation in CLND and adjuvant therapy utilization. We aimed to explore how providers consider multidisciplinary treatment options in this setting. METHODS: We conducted semi-structured interviews among surgical oncologists, medical oncologists, and otolaryngologists. Two researchers performed analysis through independent data abstraction of transcripts. Findings were discussed to reach consensus. RESULTS: All participants (n = 17) practiced at a cancer center in an academic setting. Melanoma comprised an estimated 30% to 80% of their practice (only 2% to 15% for otolaryngologists). Participants described melanoma care as inherently “multidisciplinary.” Many noted the importance of real-time conversations among providers, particularly those facilitated by shared clinic days or space, for everyday decision-making compared with formal tumor boards. Despite stating a belief that their practice mirrored other providers within and outside their institutions, participants revealed differing perspectives on CLND and adjuvant therapy (Table). Multidisciplinary care presented challenges for melanoma surveillance because surgical oncologists expressed desire to retain ownership of patients undergoing active surveillance but did not feel comfortable overseeing needs related to adjuvant therapy. Both surgical and medical oncologists noted potential redundancy in roles and burden to patients in the form of uncoordinated visits and scans. Table. - Differences in Perspectives on Completion Lymph Node Dissection (CLND) and Adjuvant Systemic Therapy Treatment option Representative example (surgical oncology) Representative example (medical oncology) Representative example (otolaryngology) Completion lymph node dissection At our institution almost never do patients get a [CLND]. Soon after the trials, there was some ambiguity about should some patients that may not have been as well represented in those trials be considered for completion, and there’s probably less issue there. Probably the main factor that pushes for dissection now would be ability to comply with routine surveillance. (Participant 7) I have seen somewhat of a push for surgery just because all of our adjuvant trials were done in patients who did have a nodal basin dissected. So it’s a little bit of a different population that we’re actually treating than was studied in [MSLT-II] because we may have patients who have residual disease. So to be more purely like the trial, there are sometimes people who push for a lymph node dissection. (Participant 1) Some of this really just relates to your philosophy of approaching cancer and surgical aggressiveness in general. I generally err on the side of being a more conservative surgeon, which applies not just to melanoma. So I am a bit more reticent to recommend a completion than some of my colleagues, but that’s not to say they’re wrong and I’m right. (Participant 14) Adjuvant systemic therapy So it’s really hard to give adjuvant therapy when there’s no survival benefit, and you see that the toxicity is so bad. From my standpoint, it’s very hard for me to think about let’s take a patient, let’s remove all of their disease, and then give them immunotherapy. Let’s boost the immune system. Oh—but I already took it all out. So the adjuvant therapy idea is hard for me. (Participant 2) We know with the Keynote 716 trial, pembrolizumab can be [used] in patients who have high risk stage II disease. Based on that trial, we are now recommending adjuvant immune therapy. So it’s kind of a continuum. Now we can justify [stage] IIIA patients that were excluded from the stage III trials. (Participant 15) A lot of these patients are going to get adjuvant therapy, no matter what, so both for immunotherapy and for like a dabrafenib or trametinib treatment. The question is not whether or not we do adjuvant therapy, the question is whether they get the [adjuvant] therapy with or without a completion lymphadenectomy. (Participant 10) CONCLUSION: Opportunities exist to improve multidisciplinary melanoma care through broader consensus of how to translate emerging data into patient care and delineating surveillance roles." @default.
• W4306252007 created "2022-10-15" @default.
• W4306252007 creator A5018317962 @default.
• W4306252007 creator A5023262629 @default.
• W4306252007 creator A5035194454 @default.
• W4306252007 creator A5045370062 @default.
• W4306252007 creator A5054803465 @default.
• W4306252007 creator A5068189427 @default.
• W4306252007 creator A5081147600 @default.
• W4306252007 date "2022-10-17" @default.
• W4306252007 modified "2023-09-27" @default.
• W4306252007 title "Implementation of Melanoma Guidelines in the Multidisciplinary Setting: A Qualitative Analysis" @default.
• W4306252007 doi "https://doi.org/10.1097/01.xcs.0000894932.53645.e1" @default.
• W4306252007 hasPublicationYear "2022" @default.
• W4306252007 type Work @default.
• W4306252007 citedByCount "0" @default.
• W4306252007 crossrefType "journal-article" @default.
• W4306252007 hasAuthorship W4306252007A5018317962 @default.
• W4306252007 hasAuthorship W4306252007A5023262629 @default.
• W4306252007 hasAuthorship W4306252007A5035194454 @default.
• W4306252007 hasAuthorship W4306252007A5045370062 @default.
• W4306252007 hasAuthorship W4306252007A5054803465 @default.
• W4306252007 hasAuthorship W4306252007A5068189427 @default.
• W4306252007 hasAuthorship W4306252007A5081147600 @default.
• W4306252007 hasBestOaLocation W43062520071 @default.
• W4306252007 hasConcept C121608353 @default.
• W4306252007 hasConcept C126322002 @default.
• W4306252007 hasConcept C141071460 @default.
• W4306252007 hasConcept C144024400 @default.
• W4306252007 hasConcept C177713679 @default.
• W4306252007 hasConcept C185926286 @default.
• W4306252007 hasConcept C22467394 @default.
• W4306252007 hasConcept C2777658100 @default.
• W4306252007 hasConcept C2777982462 @default.
• W4306252007 hasConcept C2780849966 @default.
• W4306252007 hasConcept C2780920918 @default.
• W4306252007 hasConcept C36289849 @default.
• W4306252007 hasConcept C502942594 @default.
• W4306252007 hasConcept C509974204 @default.
• W4306252007 hasConcept C512399662 @default.
• W4306252007 hasConcept C530470458 @default.
• W4306252007 hasConcept C61434518 @default.
• W4306252007 hasConcept C71924100 @default.
• W4306252007 hasConceptScore W4306252007C121608353 @default.
• W4306252007 hasConceptScore W4306252007C126322002 @default.
• W4306252007 hasConceptScore W4306252007C141071460 @default.
• W4306252007 hasConceptScore W4306252007C144024400 @default.
• W4306252007 hasConceptScore W4306252007C177713679 @default.
• W4306252007 hasConceptScore W4306252007C185926286 @default.
• W4306252007 hasConceptScore W4306252007C22467394 @default.
• W4306252007 hasConceptScore W4306252007C2777658100 @default.
• W4306252007 hasConceptScore W4306252007C2777982462 @default.
• W4306252007 hasConceptScore W4306252007C2780849966 @default.
• W4306252007 hasConceptScore W4306252007C2780920918 @default.
• W4306252007 hasConceptScore W4306252007C36289849 @default.
• W4306252007 hasConceptScore W4306252007C502942594 @default.
• W4306252007 hasConceptScore W4306252007C509974204 @default.
• W4306252007 hasConceptScore W4306252007C512399662 @default.
• W4306252007 hasConceptScore W4306252007C530470458 @default.
• W4306252007 hasConceptScore W4306252007C61434518 @default.
• W4306252007 hasConceptScore W4306252007C71924100 @default.
• W4306252007 hasIssue "5" @default.
• W4306252007 hasLocation W43062520071 @default.
• W4306252007 hasLocation W43062520072 @default.
• W4306252007 hasOpenAccess W4306252007 @default.
• W4306252007 hasPrimaryLocation W43062520071 @default.
• W4306252007 hasRelatedWork W2004009702 @default.
• W4306252007 hasRelatedWork W2061280349 @default.
• W4306252007 hasRelatedWork W2107729139 @default.
• W4306252007 hasRelatedWork W2329506905 @default.
• W4306252007 hasRelatedWork W2583950782 @default.
• W4306252007 hasRelatedWork W2912404883 @default.
• W4306252007 hasRelatedWork W3030007841 @default.
• W4306252007 hasRelatedWork W3157338522 @default.
• W4306252007 hasRelatedWork W3160730205 @default.
• W4306252007 hasRelatedWork W3186435472 @default.
• W4306252007 hasVolume "235" @default.
• W4306252007 isParatext "false" @default.
• W4306252007 isRetracted "false" @default.
• W4306252007 workType "article" @default.